WAYNE, Pa., Aug. 27, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Onyx Pharmaceuticals, Inc. ("Onyx" or the "Company") (NASDAQ: ONXX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Amgen Inc. in a transaction valued at approximately $10.4 billion.
(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )
If you own shares of Onyx would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/onxx. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Onyx for not acting in the Company's shareholders' best interests in connection with the sale process. Under the terms of the agreement, shareholders of Onyx will receive $125.00 per share in cash for each share of Onyx they own.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
CONTACT:
Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/onxx
rmaniskas@rmclasslaw.com
SOURCE Ryan & Maniskas, LLP
